Allergan to Acquire ZELTIQ aiming at body contouring segment

Medical Devices Directory Forums Business Partnering Allergan to Acquire ZELTIQ aiming at body contouring segment

This topic contains 0 replies, has 1 voice, and was last updated by  Brückenkopf GmbH 7 months, 1 week ago.

Viewing 1 post (of 1 total)
  • Author
    Posts
  • #3258

    Allergan plc and ZELTIQ® Aesthetics, Inc. announced that they have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary adjustments.
    The acquisition of ZELTIQ is immediately accretive and enhances Allergan’s global medical aesthetics portfolio with the addition of ZELTIQ’s flagship CoolSculpting® System, the sales leader in the fast-growing cash pay body contouring segment of medical aesthetics. The CoolSculpting System is FDA-cleared to affect appearance through lipolysis or reduction of unwanted fat using a patented cooling technology. CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue. Body contouring is a $4 billion market opportunity worldwide and growing.

    Source: Allergan

    Share
Viewing 1 post (of 1 total)

You must be logged in to reply to this topic.

Share